^
    Apply
    Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients (ROYAL) (NCT07151911)
    Phase N/A
    Azienda Ospedaliero-Universitaria di Modena
    Recruiting
    Last update posted :
    09/03/2025
    Initiation :
    08/26/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2031
    BRCA
    |
    Lynparza (olaparib) • Verzenio (abemaciclib)
    A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations (APEAK) (NCT06947811)
    Phase 1/2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    06/04/2025
    Initiation :
    06/09/2025
    Primary completion :
    03/01/2027
    Completion :
    03/01/2027
    KRAS
    |
    Ibrance (palbociclib) • Ameile (aumolertinib)
    Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas (NCT04750928)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/29/2021
    Primary completion :
    12/31/2028
    Completion :
    12/31/2029
    NF1
    |
    NF1 mutation
    |
    Verzenio (abemaciclib)
    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/13/2023
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    KRAS • BRAF • NRAS • HRAS • RAS
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer (NCT05996107)
    Phase 1
    University of Michigan Rogel Cancer Center
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/27/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2030
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Kisqali (ribociclib)
    Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) (NCT05038735)
    Phase 3
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/17/2021
    Primary completion :
    12/30/2025
    Completion :
    12/29/2027
    HER-2 • ER • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    Piqray (alpelisib) • fulvestrant
    Study of Ribociclib and Everolimus in HGG and DIPG (NCT05843253)
    Phase 2
    Nationwide Children's Hospital
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/22/2024
    Primary completion :
    08/28/2028
    Completion :
    08/28/2034
    PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C
    |
    PIK3CA mutation • CDKN2A deletion
    |
    everolimus • Kisqali (ribociclib)
    A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence (CAROLEEN) (NCT06830720)
    Phase N/A
    Novartis Pharmaceuticals
    Not yet recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/09/2025
    Primary completion :
    05/31/2030
    Completion :
    05/31/2030
    HER-2
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • Kisqali (ribociclib)
    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) (NCT03691493)
    Phase 2
    Emory University
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    02/08/2019
    Primary completion :
    10/13/2022
    Completion :
    10/13/2022
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (NCT05429502)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2022
    Primary completion :
    10/15/2027
    Completion :
    01/28/2028
    MYCN • SMARCB1
    |
    IDH wild-type
    |
    temozolomide • Kisqali (ribociclib) • topotecan
    Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (NCI-2018-01050) (NCT03774472)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    08/20/2018
    Primary completion :
    04/17/2024
    Completion :
    04/17/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole • hydroxychloroquine
    [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (CAAA603B12101) (NCT05870579)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/13/2023
    Primary completion :
    12/30/2026
    Completion :
    01/26/2032
    HER-2 • ER
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603